Business Wire

MA-WASABI-TECHNOLOGIES

Share
Wasabi Technologies Reinforces its Commitment to EMEA with the Appointment of Jon Howes as General Manager

Wasabi Technologies, the hot cloud storage company, strengthened its foothold in EMEA with the appointment of Jon Howes as Vice President and General Manager for EMEA. Howes will build on Wasabi’s momentous growth in the region, highlighted by a flagship deal with Liverpool Football Club, 1,800 new partners, and a nearly 90% ARR growth rate. Additionally, a full region go-to-market team has been established to support the growth of cloud storage, with Eric Peters as Country Manager of Benelux & Southern Europe based in France; Daniel Arabié, Country Manager of Central Europe/DACH based in Germany, and Kevin Dunn, Country Manager for the UK/I & Nordics based in the UK.

Jon Howes, VP and GM for EMEA, Wasabi Technologies, said: 
“Demand for predictably priced, secure, high-performance cloud storage is growing at an unprecedented pace in EMEA, making Wasabi a perfect fit for the market. Our immense traction across Europe is a testament to the value we bring to enterprises and organisations across sports, media and entertainment, surveillance, education, healthcare, and more. Being at the helm of Wasabi’s EMEA operations is a once-in-a-lifetime opportunity, and I look forward to the expansion of Wasabi hot cloud storage in this important region along with our industry-leading team.”

Howes brings more than 20 years’ experience to Wasabi, with deep expertise in scaling go-to-market models for technology companies in EMEA including Juniper Networks, Oracle and Infovista. His initial priorities will be growing Wasabi’s channel presence, scaling its partner and customer base, and strategically increasing Wasabi’s headcount in key European markets, specifically the UK, France and Germany. Meanwhile, Wasabi’s newly appointed country managers hold a plethora of proven sales and channel experience with organisations including AWS, Cloudian, EMC, Juniper Networks, Nimble Storage, and others.

Wasabi’s 'channel-first’ approach in EMEA has established partnerships with Exclusive Networks, Ebertlang, Veeam, Equinix, and more – most recently Skill Partner. Marquee customer wins include Liverpool Football Club, who migrated to Wasabi for predictable, affordable cloud storage without fees for egress or API requests in order to create a central repository for all the club’s digital media.

Drew Crisp, SVP of Digital at Liverpool Football Club, said: 
“Many cloud vendors try to be all things to all people, to the customer’s detriment. Wasabi’s singular focus on cloud storage has made them brilliant at what they do. They know the cloud storage space inside and out and have worked with us every step of the way. Not only does Liverpool FC have a very simple cost model with Wasabi as we migrate from on-premises to the cloud, we have price predictability that enables us to truly understand our total cost of ownership, which is essential for us.”

Arnaud Semont, Associate Director at Skill Partner, said: 
“Skill Partner goes to market with innovative, disruptive and predictable IT solutions, which is why we partner with Wasabi on our backup and disaster recovery services. We use Wasabi cloud storage to keep an external copy of our customers' data using immutable storage, which ensures data is safe from ransomware with object lock. As a system integrator and service provider based in EMEA, Wasabi's local storage regions help us meet data sovereignty requirements, allowing us to use the Wasabi Paris storage region with replication to Frankfurt.”

Wasabi hot cloud storage is the industry’s most reliable, scalable, and predictably priced cloud storage with no fees for egress or API requests and no vendor lock-in. Wasabi is gaining market traction at a phenomenal pace as organisations globally are looking for cloud storage solutions that fit their budgets and unique needs. It’s also an ideal product for the channel because every organisation needs to store data and Wasabi is simple to understand and integrate with other best-of-breed products. It also offers the highest level of protection in cloud storage with Object Lock immutability and 11 x 9s of data durability. Service launched in EMEA in 2019 with the opening of the Amsterdam storage region. Since then, Wasabi has added storage regions in London, Frankfurt, and Paris to support the company’s rapid growth and to meet customer data sovereignty needs.

Companies in every industry can benefit from Wasabi hot cloud storage and its suite of supporting products and tools like the recently announced Wasabi Surveillance Cloud, which delivers bottomless storage for video surveillance, and a state-of-the-art Carbon Footprint Calculator that helps customers and partners accurately measure and report on their energy use in specific Wasabi data centres as part of their broader ESG objectives.

Regularly named one of technology’s fastest-growing companies, and recognized by analysts as the top alternative to AWS S3, Wasabi has raised over $500 million in funding to support its international expansion and availability for customers of every size. For more information on how Wasabi can partner with your organisation, visit here or contact emeasales@wasabi.com.

About Wasabi Technologies 
Wasabi provides simple and affordable hot cloud storage for businesses all over the world. It enables organisations to store and instantly access an unlimited amount of data with no complex tiers or egress or API fees, delivering predictable costs that save money and industry leading security and performance businesses can count on. Trusted by customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.

Follow and connect with Wasabi on Linkedin,Twitter, Facebook, Instagram, and The Bucket.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye